Chris is a consultant with a broad background spanning over 10 years in the consulting and financial services industries. His consulting experience includes roles in performance improvement and M&A integration and separation, serving clients across several industries including healthcare, life-sciences, consumer goods, construction services, government contracting and financial services. Past engagement experience includes:- Pre-close integration and separation planning- Post-merger integration- Organizational review and redesign- Operating Model development and improvement- Business strategy development and implementationRiveron is a business advisory firm infused with entrepreneurship. Drawing on our consulting, public accounting and industry backgrounds, we approach your business with purpose and pragmatism. Our unique perspective on transactions, business transformation and accounting advisory was developed through guiding clients in times of high growth and distress, integrations and separations. We partner with private equity firms, corporations and lenders to prepare for change and deliver an unprecedented level of understanding and results. Founded in 2006 and headquartered in Dallas, Texas, Riveron has grown into eight markets across the country including Atlanta, Chicago, Denver, Houston, Minneapolis, New York and Washington D.C.

Member of the KPMG M&A Services practice working mainly for financial services clients, with additional transaction experience in the healthcare, life sciences and consumer goods sectors.My clients were primarily investment managers (traditional and alternative), but also included US bulge bracket banks, regional banks and insurance firms.Prior to my role in M&A services, I served as a generalist consultant in KPMG's financial services practice. I was previously based out of KPMG's Los Angeles, Boston and New York City offices.

Trading surveillance analytics and organizational performance improvement engagements for a major US broker-dealer.

Portfolio management: enhanced index and long/short (market neutral and 130/30) US large cap equity products